Диссертация (1140088), страница 21
Текст из файла (страница 21)
–р.135-143.118. Nestle FO, Kaplan DH, Barker J. Psoriasis. //N.Engl.J.Med.- 2009.-№361.р.496-509.119. Nograles KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines interleukin(IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-resonsepathways.// Br.J.Dermatol.- 2008.-№ 159.-р. 1092-1102.120. Nograles KA, Zaba LC, Shemer A et al. IL-22-producing “T22” T cells accountfor upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing T(H)17T cells.// J.Allergy Clin.Immunol.- 2009.-№ 123.-р.
1244-1252.121. Ong PY, Ohtake T, Brandt C et al.Endogenous antimicrobial peptides and skininfections in atopic dermatitis. //N Engl J Med.- 2002.-v. 347(15).-р.1151-1160.122. Ortega C, Fernandez-A S, Carrelo JM et al. IL-17 producing CD8+ Tlymphocytes from psoriasis skin plaques are cytotoxic effector cells that secreteTh17-related cytokines.// J.Leukoc.Biol.- 2009.-№ 86.-р. 435-443.123. Ortonne JP, Ganslandt C, Tan J et al. Quality of life in patients with scalppsoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: arandomized controlled trial.// J Eur Acad Dermatol Venereol.- 2009.-№ 23.- 919–926.124. Otkjaer K, Kragballe K, Funding AT et al. The dynamics of gene expression ofinterleukin-19 and interleukin-20 and their receptors in psoriasis.// Br.J.Dermatol.2005.
-№153.-р. 911-918.125. Ozawa M, Ferenczi K, Kikuchi T et al 312-nanometer ultraviolet B light(narrow-band UVB) induces apoptosis of T cells within psoriatic lesions.// LabInvest Dermatol.- 1999.-№ 189.- р.711-718.121126. Ozdamar SO, Seckin D, Kandemir B et al. Mast cells in psoriasis.//Dermatology.- 1996.-v. 192(2). –р.190.127. Palota T, Szepietowski JC, Pec J et al. A survey of disease severity, quality oflife, and treatment patterns of biologically naive patients with psoriasis in centraland eastern Europe.// Acta Dermatovenerol Croat.- 2010,-№ 18.-р. 151–161.128.
Pariser DM, Bagel J, Gelfand JM et al. National Psoriasis Foundation clinicalconsensus on disease severity.// Archives of dermatology.- 2007.-№ 143.-р.239–242.129. Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: asystematic review of incidence and prevalence. // J Invest Dermatol. - 2013 – v.133- №2 – р.377-385.130.Parrish L. Psoriasis: symptoms, treatments and its impact on quality of life. //Br J Community Nurs. -2012.-v.
17(11).-р.524-528.131. Parrish J.A., Jaenicke K.F. Action spectrum for phototherapy of psoriasis// JInvest Dermatol. – 1981.-№ 76.-р. 359 - 362.132. Pauls K, Schon M, Kubitza R et al. Role integrin άE(CD103)β7 for tissue–specific epidermal localization of CD8+t lymphocytes.// J.Invest.Dermatol.- 2001.№117.-р.
569-575.133. Perez-Lorenzo R., Zambrano-Zaragoza J.F., Moo-Castillo K. et al. IgG classantibodies to heat shock- induced streptococcal antigens in psoriatic patients // Int.J. Dermatol. — 2003.-v.42(2).-р.110-115.134. Peric M, Koglin Y, Dombrowski Y. et al. Vitamin D analog differentially controlantimicrobial peptide «alarmin» expression in psoriasis.// PloS One.- 2009. –v.4(7).eb340.135. Qu N, Xu M, Mizoguchi I.et al.Pivotal roles of T-helper 17-related cytokines,IL-17, IL-22, and IL-23, in inflammatory diseases.// Clin Dev Immunol. -2013.№2013.-р.968549.136. Ramgolam VS, Sha Y, Jin J et al.
IFN-β inhibits human Th17 celldifferentiation.// J.Immunol. -2009. -№183.-р. 5418-5427.122137. Ravić-Nikolić A1, Radosavljević G, Jovanović I. et al. Systemicphotochemotherapy decreases the expression of IFN-γ, IL-12p40 and IL-23p19 inpsoriatic plaques.// Eur J Dermatol.- 2011.-v.21(1).-р.53-57.138. Raychaudhuri SP, Farber EM The prevalence of psoriasis in the world.// J EurAcad Dermatol Venereol.- 2001.-№ 15.-р. 16–17.139.Reich K. The concept of psoriasis as a systemic inflammation: implications fordisease management.// JEADV.- 2012.-№ 26 (Suppl. 2).-р. 3–11140. Reich K, Griffiths CE The relationship between quality of life and skinclearance in moderate-to-severe psoriasis: lessons learnt from clinical trials withinfliximab.// Arch Dermatol Res ,-2008.-№300.-р. 537–544.141.
Res PMC, Piskin G, de Boer OJ et al. Overrepresentation of IL-17A and IL-22producing CD8 T cells in lesional skin suggests their involvement in thepathogenesis psoriasis.// PloS ONE.- 2010.-№ 5.-р. 1-11.142. Revicki DA, Menter A, Feldman S et al. Adalimumab improves health-relatedquality of life in patients with moderate to severe plaque psoriasis compared withthe United States general population norms: results from a randomized, controlledPhase III study.// Health Qual Life Outcomes.-2008.-№ 6.-р. 75.143. Rosenberg P, Urwitz H, Johannesson A et al. Psoriasis patients with diabetestype 2 are at high risk of develop- ing liver fibrosis during methotrexate treatment.//J Hepatol .-2007.-№ 46.-р.1111–1118.144.
Saad AA, Ashcroft DM, Watson KD et al. Improvements in quality of life andfunctional status in patients with psoriatic arthritis receiving anti-tumor necrosisfactor therapies.// Arthritis Care Res (Hoboken).- 2010.-v. 62(3).-р. 345–353.145.
Sandgren S, Wittrup A, Chen et al. The human antimicrobial peptide LL-37transfers extracellular DNA plasmid in nuclear compartment of mammalian cells vialipid rafts and proteoglycan-dependent endocytosis.// J.Biol.Chem.-2004.-№ 27.-р.17951-17958.146. Sano S et al. Stat3 links activated keratinocytes and immunocytes required fordevelopment of psoriasis in a novel transgenic mouse model.// Nat.Med.- 2005.№11.-р. 43-49.123147. Schauber J, Ruzicka T, Rupec RA.
Cathelicidin LL-37. A central factor in thepathogenesis of inflammatory dermatoses?// Hautarzt.- 2008.-v. 59(1).-р.72-74.148. Schlaak JF, Buslau M, Jochum W et al. T cells involved in psoriasis vulgarisbelong to the Th1 subset.// J Invest Dermatol.- 1994.-№102.-р.145–149.149. Shepherd J, Little MC, Nicklin J et al. Psoriasis-like cutaneous inflammation inmice lacking interleukin-1 receptor antagonist.// J.Invest.Dermatol.- 2004.-№ 122.р. 665-669.150. Sigmundsdottir H, Johnston A, Gudjonsson JE.et al.Narrowband-UVBirradiation decreases the production of pro-inflammatory cytokines by stimulated Tcells.// Arch Dermatol Res.- 2005.-№297.-р.39–42.151. Singh TP, Schon MP, Wallbrecht K et al.
8-methoxypsoralen plus ultravioletA therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder.// JImmunol.- 2010.-№184.-р.7257–7267.152. Skov L, Hansen H, Allen N et al. Contrasting effects of ultraviolet A1 andultraviolet B exposure on the induction of tumour necrosis factor-alpha in humanskin.// Br J Dermatol.- 1998.-№138.-р.216–220.153. Soyland E, Heier I, Rodriguez-Gallego C et al. Sun exposure induces rapidimmunological changes in skin and peripheral blood in patients with psoriasis.// BrJ Dermatol.- 2011.-№164.-р.344–355.154.
Spandonaro F, Altomare G, Berardesca E et al. Health-related quality of lifein psoriasis: an analysis of Psocare project patients.// G Ital Dermatol Venereol.2011.-№ 146.-р. 169–177.155. Stenderup K, Rosada C, Worsaae A et al. Interleukin-20 plays a critical role inmaintenance and development of psoriasis in the human xenograft transplantationmodel.// Br.J.Dermatol.- 2009.-№ 160.-р. 284-296.156.Stern RS, Nijsten T, Feldman SR et al.
Psoriasis is common, carries a substantialburden even when not extensive, and is associated with widespread treatmentdissatisfaction.// J Investig Dermatol Symp Proc.- 2004.-v. 9(2).-р. 136–139.124157. Tidman MJ. Improving outcomes in patients with psoriasis.// Practitioner. 2013.-v. 257(1757).-р.27-30.158. Tohyama M, Hanakawa Y, Shiraka.ta Y.et al IL-17 and IL-22 mediate IL-20subfamily cytokine production in cultured keratinocytes via increased IL-22 receptorexpression.// Eur J Immunol. -2009. –v.39(10).-р. 2779-2788.159. Tohyama M, Yang L, Hanakawa Y.et al. IFN-α enhances IL-22 receptorexpression in keratinocytes: a possible role in the development of psoriasis.// J InvestDermatol.- 2012. –v.132(7).-р. 1933-1935.160.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
